Association Between Reduced Levels of Alkaline Phosphatase and Survival Times of Patients With Primary Sclerosing Cholangitis

There is no significant difference in long-term survival between patients with PSC given UDCA (17-23 mg/kg/day) or placebo for 5 years. However, patients who have reduced or normal levels of ALP have longer survival times, regardless of whether they receive UDCA or placebo.